Please assess the completion status of the following clinical trial:

Trial Title: Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 6 and \< 18 years of age~* ≥ 18 kg (\~ 40 lbs.)~* TS diagnosis and both motor and vocal tics that cause impairment with normal routines~* Minimum score of 20 on the YGTSS-Total Tic Score~* May not be taking any medications used to treat motor or vocal tics for at least 14 days prior to Baseline.~* Effective contraception during the study and 30 days after last study dose for sexually active subjects~Exclusion Criteria:~* Certain mood or psychiatric disorders (i.e., dementia, bipolar disorder, schizophrenia, major depressive disorder)~* Unstable medical illness or clinically significant lab abnormalities~* Risk of suicide~* Pregnant or lactating women~* Moderate to severe renal insufficiency~* Hepatic insufficiency~* Positive urine drug screen~* Unstable doses for drugs to treat anxiety, depression, Attention Deficit Hyperactivity Disorder~* Certain medications that would lead to drug interactions~* Recent behavioral therapy

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ecopipam HCI 2 mg/kg/day (Type: EXPERIMENTAL): Ecopipam HCl 12.5-, 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo tablets taken orally in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).